{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-057516","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.555885+00:00","generated_at":"2026-06-15T09:10:49.015308+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"uniQure Q1 net loss $77.2M ($1.63/shr); cash $315.3M; on track for AMT-130 data Q2","bullets":["Revenue $5.3M (up from $1.8M YoY) on $4.9M contract manufacturing for HEMGENIX.","Eligible for $100M milestone from CSL on first US commercial sale of HEMGENIX; $75M European milestone by July 2, 2023.","Huntington's disease AMT-130: 1-2 year follow-up data from US Phase I/II expected Q2 2023; higher-dose enrollment in EU trial to complete mid-2023.","Pipeline advancing: AMT-162 (SOD1-ALS) Phase I/II start H2 2023; AMT-260 (epilepsy) and AMT-191 (Fabry) IND filings in 2023.","Cash $315.3M expected to fund operations into 2025 ($100M milestone assumed) or H1 2025 if $75M European milestone achieved."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-057516","json":"https://secwatch.observer/filing/0001104659-23-057516.json","markdown":"https://secwatch.observer/filing/0001104659-23-057516.md","text":"https://secwatch.observer/filing/0001104659-23-057516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923057516/0001104659-23-057516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923057516/tm2315123d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:10:49.015308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5dcf14cc7c63a7752a30329e285d8c5576369bcb","claim":"uniQure N.V. reported the first quarter of 2023 results: revenue $5.3 million.","evidence_excerpt":"Revenue for the three months ended March 31, 2023 was $5.3 million, compared to $1.8 million in the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923057516/0001104659-23-057516-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Revenue","value":"$5.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}